ANTIOXIDANT ENZYMES STATUS AND THYROID STIMULATING HORMONE LEVEL OF DOWN SYNDROME PATIENT IN WEST BENGAL, INDIA: A CASE-CONTROL STUDY

GARGI PODDER*1, ANIKET ADHIKARI1, AULEY DE1, JAYSHREE BANERJEE2, MADHUSNATA DE2

1Research Scholar, 2Professor Department of Genetics, Ramakrishna Mission Seva Pratishthan,Vivekananda Institute of Medical Sciences, 99 Sarat Bose Road, Kolkata-700026. Email: gargi.podder86@gmail.com

Received: 29 September 2013, Revised and Accepted: 19 October 2013

ABSTRACT

Objective: The copper-zinc superoxide dismutase gene resides on chromosome 21 and is over expressed in Down syndrome patients. Reactive oxygen species can initiate lipid peroxidation and DNA damage leading to mutagenesis, carcinogenesis and cell death, if the antioxidant system is impaired. Down syndrome is associated with various forms of thyroid dysfunction, hypothyroidism being the most common. The additive effects of both genetic and extrinsic factors contribute to further amplification of the clinical problems in children with Down syndrome. For the objective of the current study is to evaluate the activities of some antioxidant enzymes like superoxide dismutase and glutathione peroxidase and level of thyroid stimulating hormone among Down syndrome patients and then compare with healthy control groups.

Methods: The present work aimed to study the changes in the quantitative in vitro activities of the antioxidant enzymes – glutathione peroxidase and superoxide dismutase in the erythrocyte and thyroid stimulating hormone level of the study group. This study group included both Down syndrome patients and age, sex matched healthy controls.

Results: It was found that significant increase in the activities of both glutathione peroxidase and superoxide dismutase and thyroid stimulating hormone level in patients as compared with healthy controls. This study has revealed that increased antioxidant enzymes activity and thyroid stimulating hormone level are the two significant indicators of Down syndrome patients.

Conclusion: Study of biochemical parameter reveals that Thyroid stimulating hormone level, Glutathione peroxidase and Superoxide dismutase activity is increased among DS cases.

Keywords: Down syndrome, Glutathione peroxidase, Superoxide dismutase, Thyroid stimulating hormone, Trisomy 21.

INTRODUCTION

Down syndrome or Down’s syndrome (DS) is the most common chromosomal disease, consisting of a trisomy of the 21st chromosome, occurring in 1 in 600 to 1 in 800 live births [1]. The distal segment of this chromosome is the site of the gene encoding the synapsis of SOD. It has been suggested that the excess of genetic information in DS patients is the cause of an increase in the activity of SOD1 in these patients [2,3]. It has been hypothesized that an increase in oxidative stress in patients with DS would account for the appearance of different diseases, such as atherosclerosis, accelerated cell aging, cellular mutagenicity, and the neurologic disorders that often occur in these patients [4].

Reactive oxygen (RO) species are substances that are released during oxidative metabolism. RO species include the superoxide anion (O₂⁻), hydrogen peroxide (H₂O₂), and the hydroxyl radical (OH). The reactions of RO species with macromolecules can lead to DNA mutations, changes in the structure and function of proteins, and peroxidative damage of cell-membrane lipids [5]. There is a primary defense system against oxidative stress, mediated by sequential enzymatic reactions. In the first step of the process, CuZn-superoxide dismutase (SOD1) catalyzes the dismutation of O₂ to H₂O₂. Glutathione peroxidase (GPx) then independently converts H₂O₂ to water [6]. Any increase in SOD1 catalytic activity, therefore, produces an excess of H₂O₂ that must be efficiently neutralized by either GPx or catalase [7].

Several groups have proposed that many of the neurologic symptoms of Down syndrome result from the increased intracellular activity of cytosolic copper/zinc superoxide dismutase (Sod1), an enzyme coded on chromosome 21 (21q22.1), which converts the superoxide radical into hydrogen peroxide. Sod1 is a constitutive enzyme with activity that is increased by 50% in patients with trisomy 21. supporters of the hypothesis of Sod1-induced damage in Down syndrome assumed that increased Sod1 activity causes an imbalance in the steady-state oxidative stress that increases formation of hydrogen peroxide and other oxidants such as the hydroxyl radical [4]. Erythrocytes are peroxisome in an environment in which they are constantly exposed to both extracellular and intracellular sources of reactive oxygen species. The conversion of oxyhemoglobin to methemoglobin inside the erythrocyte results in the concomitant production of O₂⁻. Oxidative damage can alter membrane components and, consequently, erythrocyte membrane fluidity [8].

The most common autoimmune disease in Down syndrome is related to the thyroid gland. Thyroid auto-antibodies are found in 13-34% of patients with Down syndrome [9]. The clinical symptoms and signs of both Down syndrome and hypothyroidism are overlapping to some extent e.g. hypotonia, lethargy, dullness, mental retardation, growth failure, prolonged neonatal jaundice, delayed closure fontanellae, macroglossia, obesity etc. Thus, both hypothyroidism and hyperthyroidism are more common in patients with Down syndrome than in the general population [10].

This work aims to evaluate the levels of superoxide dismutase and glutathione peroxidase activities and serum level thyroid stimulating hormone (TSH). A possible erythrocytic lysis and the consequent leaching of enzymes, erythrocyte osmotic fragility, and haemograms of people with Down syndrome were evaluated.

PARTICIPANTS AND METHODS

Study group

Our study group comprised of 115 individuals, which include both Down syndrome patients (n=88) and age, sex-matched healthy control (n=30). The studied population belonged to ages ranging from 2 days to 30 years. Among the patients studied, 55 were male and 30 were female individuals. Among the control population studied, 17 were male and 13 were female individuals. The studied population came from mainly lower socio-economic strata of the society. So, maximum patient’s parental literacy and family income were very low. Cause of that, they are not properly aware about genetic abnormality. Down syndrome individuals were distributed according to their age.
Ethical Clearance
The studies involving human subjects were reviewed and approved by the ethical committee of the Vivekananda Institute of Medical Sciences. All individuals were included in this study only after the Informed Consent of their parents.

Estimation of glutathione peroxidase activity
This method is based on Paglia and Valentine (1967) [11]. Glutathione Peroxidase catalyzes the oxidation of Glutathione (GSH) by Cumene Hydroperoxide. In the presence of Glutathione Reductase and NADPH the oxidized Glutathione (GS)G) is immediately converted to the reduced form with a concomitant oxidation of NADPH to NADP+. The decrease in absorbance at 340nm is measured. Quantitative in vitro determination of glutathione peroxidase activities in whole blood were estimated with 0.05ml heparinized whole blood using Ransod glutathione peroxidase assay kit (Randox, United Kingdom). The samples were assayed by UV-Visible spectrophotometer (Spectronic, USA) at a wavelength of 340nm. Appropriate negative and positive controls were maintained with each batch of estimation.

Estimation of Superoxide Dismutase Activity
This method employs xanthine and xanthine oxidase (XOD) to generate superoxide radicals which react with 2-(4-iodophenyl)-3-(4-nitrophenol)-5-phenyltetrazolium chloride (N.T.) to form a red formazan dye [12]. The superoxide dismutase activity is then measured by the degree of inhibition of this reaction. One unit of SOD is that which causes a 50% inhibition of the rate of reduction of N.T. under the conditions of the assay. Quantitative in vitro determination of superoxide dismutase activities in whole blood were estimated with 0.5ml heparinized whole blood using Ransod superoxide dismutase assay kit (Randox, United Kingdom). The whole blood was centrifuged at 3000 rpm for 10 mins followed by aspiration of plasma to obtain the erythrocytes which were washed with 0.9% NaCl solution. The erythrocytes were made upto 2ml with cold redistilled water followed by incubation at 4°C. The lysate was assayed by UV-Visible spectrophotometer (Spectronic, USA) at a wavelength of 505 nm. Appropriate negative and positive controls were maintained with each batch of estimation.

Estimation of Serum level TSH
Total serum was separated out and kept in a clean sterile micro centrifuge tube (1.5ml Tarson). Thyroid Stimulating Hormone (TSH) was estimated by Vitros EciOrtho Clinical Diagnosis (Jonson & Jonson), autoanayser from the blood serum.

Erythrocyte osmotic fragility Test
It was assessed by adding 0.05 mL of fresh whole blood to various concentrations of aqueous sodium chloride and incubating the mixture for 15 minutes at room temperature. After incubation, the mixture were centrifuged, and the percentage hemolysis was determined spectrophotometrically at 540 nm by measuring the absorbance of released hemoglobin [13]. The fragility was considered to have increased when at least 1 of 12 dilutions resulted in an elevation of the hemolytic values to the sodium chloride concentration used.

Complete Haemogram
The Haemoglobin (Hb), Total count of WBC, Platelet count, Mean Corpuscular Volume (MCV), Mean Corpuscular Haemoglobin (MCH), and Mean Corpuscular Haemoglobin concentration (MCHC) were estimated by Sysmex K-2000, automated cell counter.

Statistical analysis
Statistical analyses of the experiments were done by Student’s r test.

RESULTS AND DISCUSSION
Quantitative in vitro glutathione peroxidase (Gpx) activity and superoxide dismutase (SOD) activity and TSH level were estimated in both patients and healthy controls (Table 1).

Table 1: Glutathione Peroxidase and superoxide dismutase activity of the Down syndrome patients and control group

<table>
<thead>
<tr>
<th>Types</th>
<th>No. of individuals</th>
<th>Glutathione peroxidase activity (U/g Hb) Mean±S.E</th>
<th>Superoxide dismutase activity (U/g Hb) Mean±S.E</th>
<th>Thyroid stimulating hormone (mIU/ml) Mean±S.E</th>
</tr>
</thead>
<tbody>
<tr>
<td>Healthy control</td>
<td>30</td>
<td>23.56±2.28</td>
<td>1221.46±13.32</td>
<td>3.79±0.47</td>
</tr>
<tr>
<td>Patient</td>
<td>85</td>
<td>47.14±1.06*</td>
<td>1875.79±40.46*</td>
<td>10.67±0.897*</td>
</tr>
</tbody>
</table>

*Statistically significant at P ≤ 0.001 (student t test)

In current study glutathione peroxidase activity showed about 2 fold increase as compared to healthy individuals (p≤0.001). Glutathione peroxidase activities and Superoxide dismutase were studied in different age group of patients (Table 2).

Table 2: Glutathione Peroxidase, Superoxide dismutase activities and Thyroid stimulating hormone levels according to different age group of the Down syndrome cases

<table>
<thead>
<tr>
<th>Age</th>
<th>Groups</th>
<th>Total No. of individuals</th>
<th>Male % present</th>
<th>Female % present</th>
<th>Glutathione peroxidase activity (U/g Hb) Mean±S.E</th>
<th>Superoxide dismutase activity (U/g Hb) Mean±S.E</th>
<th>Thyroid stimulating hormone (mIU/ml) Mean±S.E</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 12 months</td>
<td>I</td>
<td>44</td>
<td>37.65</td>
<td>14.12</td>
<td>41.92±1.47</td>
<td>1851.56±65.26</td>
<td>13.33±1.43</td>
</tr>
<tr>
<td>1 yr-4 yr 11 months</td>
<td>II</td>
<td>24</td>
<td>15.29</td>
<td>12.94</td>
<td>46.31±1.84</td>
<td>1789.74±61.04</td>
<td>6.24±1.39</td>
</tr>
<tr>
<td>5 yr-9yr 11 months</td>
<td>III</td>
<td>6</td>
<td>2.35</td>
<td>4.71</td>
<td>43.95±3.49</td>
<td>1978.85±98.74</td>
<td>7.38±2.59</td>
</tr>
<tr>
<td>10yr-14yr 11 months</td>
<td>IV</td>
<td>2</td>
<td>2.35</td>
<td>0</td>
<td>48.63±2.92</td>
<td>1762.3±181.15</td>
<td>9.56±3.38</td>
</tr>
<tr>
<td>15yr-19yr 11 months</td>
<td>V</td>
<td>5</td>
<td>4.71</td>
<td>1.17</td>
<td>49.21±1.81</td>
<td>1978.51±167.82</td>
<td>10.13±4.55</td>
</tr>
<tr>
<td>&gt; 20 yrs</td>
<td>VI</td>
<td>4</td>
<td>2.35</td>
<td>2.35</td>
<td>54.735±4.45</td>
<td>1860.59±90.32</td>
<td>14.75±1.33</td>
</tr>
</tbody>
</table>

It was observed that >20 years age group of patients showed the highest glutathione peroxidase activity values (54.735±4.45 U/g Hb) among all age groups. In this study superoxide dismutase activity of the patients showed about 1.5 fold increase as compared to healthy individuals (p≤0.001). Group V (15 yr -19yr 11 month’s age) patients showed the highest superoxide dismutase activity values (1978.31±167.82 U/g Hb) among all groups of patients.
The serum level Thyroid Stimulating Hormone showed about 3 fold increase as compared to healthy individuals (p<0.001).

The detailed hematological profile and fragility of red blood cell were studied by hemogram (Table 3) and erythrocyte osmotic fragility (Table 4) test. Although individuals with Down syndrome have had a slightly increase erythrocyte osmotic fragility than control group, the difference was statistically insignificant. These results, along with the normal hemogram values, indicate that there was probably no erythrocyte lysis in the Down syndrome group.

### Table 3: Complete haemogram of the study group

<table>
<thead>
<tr>
<th>Types</th>
<th>No. of individuals</th>
<th>Total count of WBC (x10⁹/µl) Mean±S.E</th>
<th>Total count of RBC (x10¹²/µl) Mean±S.E</th>
<th>Hb (g/dl) Mean±S.E</th>
<th>HCT (%) Mean±S.E</th>
<th>MCV (fl) Mean±S.E</th>
<th>MCH (pg) Mean±S.E</th>
<th>MCHC (g/dl) Mean±S.E</th>
<th>Platelet count (x10⁹/µl) Mean±S.E</th>
</tr>
</thead>
<tbody>
<tr>
<td>Healthy</td>
<td>control</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient</td>
<td>85</td>
<td>10.04±0.8</td>
<td>4.92±0.3</td>
<td>12.54</td>
<td>38.02±1.03</td>
<td>86.44</td>
<td>23.7±0.45</td>
<td>30.34±0.9</td>
<td>280.5±14.3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>8.83±0.25</td>
<td>4.49±0.2</td>
<td>10.61</td>
<td>39.38±0.75</td>
<td>71.48</td>
<td>28.09±0.54</td>
<td>34.2±0.5</td>
<td>241.65±4.96</td>
</tr>
</tbody>
</table>

Many papers have reported investigations of oxygen metabolism in trisomy 21 patients (Down syndrome) and there have been suggestions that some of the pathological symptoms of this disease, for example premature ageing, or specific brain lesion, result from the increase of the oxidative damage inside the cells [14,15]. One of the observed and probable defense mechanisms of the cell against the oxidative damage is the increase of catalytic activity of enzymes superoxide dismutase, and glutathione peroxidase counteracting toxic oxygen derivatives [15,16]. Glutathione peroxidase catalyses the reduction of hydrogen peroxide and organic hydroperoxides to alcohols of lower toxicity, thus forming the first line of defense against peroxidative damage of unsaturated lipids [17]. The gene for glutathione peroxidase synthesis is situated on chromosome no. 3 and for this reason the increase of the glutathione peroxidase activity in trisomy 21 patients is not caused by a gene dosage effect [18]. The higher activity of the enzyme in the cells may be explained as one of the mechanisms controlling the response to an acceleration of oxidative processes inside the trisomic 21 cells.

The results of biochemical analysis showed elevated activities of GPx and SOD. The variations in the activities of antioxidant enzymes were statistically significant (p ≤ 0.001).

### Table 4: Erythrocyte Osmotic Fragility test of the studied population

<table>
<thead>
<tr>
<th>Types</th>
<th>No. of individuals</th>
<th>0.2% NaCl Concentration Mean±S.E</th>
<th>0.3% NaCl Concentration Mean±S.E</th>
<th>0.4% NaCl Concentration Mean±S.E</th>
<th>0.5% NaCl Concentration Mean±S.E</th>
<th>0.6% NaCl Concentration Mean±S.E</th>
</tr>
</thead>
<tbody>
<tr>
<td>Healthy</td>
<td>control</td>
<td>0.32±0.054</td>
<td>0.45±0.022</td>
<td>0.69±0.075</td>
<td>0.84±0.09</td>
<td>0.94±0.031</td>
</tr>
<tr>
<td>Patient</td>
<td>85</td>
<td>0.639±0.032</td>
<td>0.708±0.033</td>
<td>1.11±0.035</td>
<td>1.286±0.04</td>
<td></td>
</tr>
</tbody>
</table>

Similar results were reported by Goyal et al. (2010) [27]. The SOD levels in blood were significantly higher (p<0.008) in children with Down syndrome (mean=313.7IU/ml) as compared to the control group (mean=140.4IU/ml). The findings indicate dyslipidemia and increased SOD activity in individuals with Down syndrome. The raised antioxidant activity of SOD, because of over expression of genes situated on chromosome 21, probably offers some protection against the development of atherosclerosis despite the occurrence of dyslipidemia. The current study may contribute towards a better understanding of the importance of antioxidants in protection against atherosclerosis in hypertriglyceridemia. Patients with Down syndrome have elevated levels of oxidative stress. Antioxidants have been shown to prevent the destruction of β-cells by inhibiting the peroxidation chain reaction [28]. Hence, a therapeutic trial of antioxidants in patients with Down syndrome may be beneficial in reducing morbidity. Transient hypothyroidism is the most common form of thyroid dysfunction observed in Down syndrome patients. Mark Selikowitz (1993) [29] had observed in his longitudinal study that 40% of these cases of compensated hypothyroidism resolved spontaneously. Gibson et al. (2005) [30] observed that 47% of subclinical hypothyroid Down syndrome patients were subsequently found to have normal TSH levels after a gap of four to six years.

The acquired form of hypothyroidism is usually associated with thyroid antibodies of different types and is more common in children above 8 years. Hypothyroidism was observed in 20% of the cases between 9 - 12 years [30]. Hypothyroidism develops in one third of patients with Down syndrome before the age of 25 years. Autoimmune thyroid disease is uncommon in preschool children with Down syndrome, but occurs commonly after the age of 8 years. Because symptoms of hypothyroidism might be mistaken for symptoms related to the natural course of Down syndrome, so it is important to screen annually for thyroid function [31].

In our study, the Down syndrome group had statistically significant (p ≤ 0.001) increase in TSH levels compared to control. A comparison was made among the different age groups of patients with respect to the Thyroid Stimulating Hormone (TSH) level. It was found that the level of TSH was highest in the age group above 20 years among all age group of patients.
TSH levels were found to have a positive correlation with blood pressure [32]. Reasons for the condition's heterogeneity were clarified by the discovery of thyroid stimulating hormone receptor blocking and enhancing immunoglobulins, which affect selectively hormone synthesis and thyroid gland growth [33].

CONCLUSION

The findings of this study indicated there is increased SOD and GPx activity in patients with Down syndrome. The raised antioxidant activity of SOD, because of over expression of genes situated on chromosome 21, probably offers some protection against the development of atherosclerosis and raised GPx activity of neutralizing increased activity of SOD enzymes. The current study may contribute towards a better understanding of the importance of antioxidants in Down syndrome and also the need to re-assess treatment strategies in case of those patients.

ACKNOWLEDGEMENTS

This study was financially supported by the grants from Vivekananda Institute of Medical Sciences, Kolkata. We are grateful to the Secretary, Ramakrishna Mission Seva Pratishthan, Vivekananda Institute of Medical Sciences, Kolkata for the necessary permission to carry out this study. We are also thankful to Mr. Mondal Bera for technical assistance.

REFERENCE